Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) unit Zhejiang Xinghao Pengbo Pharmaceutical started phase 2 trials for the XH-S003 drug for glomerular or kidney filtration system diseases, according to a Tuesday filing with the Hong Kong Exchange.
The drug is indicated for glomerular diseases with abnormal complement activation such as IgA nephropathy, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.